2026 Canine Degenerative Myelopathy

About this funding opportunity

Cookies Settings

We use cookies to enhance your browsing experience, serve personalised ads or content, and analyse our traffic. By clicking "Accept All", you consent to our use of cookies.

PreferencesReject AllAccept All

Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site.

We also use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent.

You can choose to enable or disable some or all of these cookies but disabling some of them may affect your browsing experience.

NecessaryAlways Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

No cookies to display.

Reject All Save My Preferences Accept All

Go Back

Go Back 2026 Canine Degenerative Myelopathy

Application Deadline

The request for proposals follows a two-tiered system of competitive review. Applicants must submit a Pre-Proposal Application through the online application system that demonstrates meritorious work closely aligned with CHF’s mission to prevent, treat, and cure canine disease. A review committee will invite some Pre-Proposal applicants to submit a Full Proposal due at 11:59PM ET on Monday, June 1, 2026.

Applications will be reviewed and awards may be determined on a rolling basis upon submission.

Pre-Proposal Due:

Tuesday, Mar 31st

Proposal Invite Issued:

~Friday, Apr 24th

Full Proposal Due:

Monday, June 1st unless otherwise noted

Notifications:

Late Summer 2026

OAK

For studies >$30,000 including 15% maximum indirect costs.

Start Oak Pre-Proposal

ACORN

For studies up to $30,000 including 15% maximum indirect costs.

Start Acorn Pre-Proposal

Scope

Research Focus Area

Project Budget

Project Period

Eligibility and Evaluation Criteria

Contact Scope

The AKC Canine Health Foundation (CHF) invites pre-proposals for research that advances progress in treating, curing, or better management of degenerative myelopathy (DM) in dogs. This grant opportunity is made possible through the generosity of a dedicated donor, Bubba’s Buddies, who shares our vision to improve the quality of life for all dogs affected by this neurodegenerative disease.

CHF welcomes innovative approaches that may include, but are not limited to: Therapeutic strategies: development or testing of interventions to slow or halt disease progression. Diagnostic advancements: biomarkers or tools to improve early and accurate identification. Disease management: supportive care strategies that improve quality of life and mobility. Translational relevance: research that may accelerate progress from discovery to…

Topic areas: Life Sciences and Health.

Funding amount

This grant provides Varies in funding.

Deadline

Applications are accepted on a rolling basis; there is no single fixed deadline.

Who can apply

This opportunity is open to the following applicant types:

• Not specified by the program.

Eligibility

The program did not publish a separate eligibility statement. See the official opportunity page for the full eligibility criteria.

Agency

2026 Canine Degenerative Myelopathy is administered by AKC Canine Health Foundation (AKC CHF), listed via AKC Canine Health Foundation.